137 related articles for article (PubMed ID: 33444077)
21. PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants.
Jahanseir K; Xing D; Greipp PT; Sukov WR; Keeney GL; Howitt BE; Schoolmeester JK
Int J Gynecol Pathol; 2018 Nov; 37(6):537-546. PubMed ID: 29140881
[TBL] [Abstract][Full Text] [Related]
22. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34.
Aiba S; Tabata N; Ishii H; Ootani H; Tagami H
Br J Dermatol; 1992 Aug; 127(2):79-84. PubMed ID: 1382538
[TBL] [Abstract][Full Text] [Related]
23. Application of COL1A1-PDGFB fusion gene detection by fluorescence in situ hybridization in biopsy tissue of dermatofibrosarcoma protuberans.
Zhang Z; Chen H; Chen M; He X; Wang Y; Zhang H
J Dermatol; 2017 Jul; 44(7):798-802. PubMed ID: 28150334
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans.
Karanian M; Pérot G; Coindre JM; Chibon F; Pedeutour F; Neuville A
Mod Pathol; 2015 Feb; 28(2):230-7. PubMed ID: 25081750
[TBL] [Abstract][Full Text] [Related]
26. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.
Mentzel T; Schärer L; Kazakov DV; Michal M
Am J Dermatopathol; 2007 Oct; 29(5):443-8. PubMed ID: 17890911
[TBL] [Abstract][Full Text] [Related]
27. Dermatofibrosarcoma Protuberans: An Immunomarker Study of 57 Cases That Included Putative Mesenchymal Stem Cell Markers.
Song JS; Kim EJ; Park CS; Cho KJ
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):586-591. PubMed ID: 28362700
[TBL] [Abstract][Full Text] [Related]
28. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma.
Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O
J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939
[No Abstract] [Full Text] [Related]
29. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
30. PDGFB RNA in situ hybridization for the diagnosis of dermatofibrosarcoma protuberans.
Cloutier JM; Allard G; Bean GR; Hornick JL; Charville GW
Mod Pathol; 2021 Aug; 34(8):1521-1529. PubMed ID: 33762682
[TBL] [Abstract][Full Text] [Related]
31. Subcutaneous dermatofibrosarcoma protuberans, a rare subtype with predilection for the head: A retrospective series of 18 cases.
Llombart B; Serra-Guillén C; Rubio L; Nagore E; Requena C; Traves V; Calomarde L; Bancalari B; López-Guerrero JA; Guillen-Barona C; Sanmartín O
J Am Acad Dermatol; 2017 Sep; 77(3):503-511.e1. PubMed ID: 28420485
[TBL] [Abstract][Full Text] [Related]
32. Alteration of PDGFRβ-Akt-mTOR pathway signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Hiraki-Hotokebuchi Y; Yamada Y; Kohashi K; Yamamoto H; Endo M; Setsu N; Yuki K; Ito T; Iwamoto Y; Furue M; Oda Y
Hum Pathol; 2017 Sep; 67():60-68. PubMed ID: 28711648
[TBL] [Abstract][Full Text] [Related]
33. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
34. Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans.
Schechter SA; Bresler SC; Patel RM
J Cutan Pathol; 2020 Oct; 47(10):913-916. PubMed ID: 32412128
[TBL] [Abstract][Full Text] [Related]
35. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays.
Patel KU; Szabo SS; Hernandez VS; Prieto VG; Abruzzo LV; Lazar AJ; López-Terrada D
Hum Pathol; 2008 Feb; 39(2):184-93. PubMed ID: 17950782
[TBL] [Abstract][Full Text] [Related]
36. Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.
Iwasaki T; Yamamoto H; Oda Y
Curr Treat Options Oncol; 2019 Mar; 20(4):29. PubMed ID: 30874910
[TBL] [Abstract][Full Text] [Related]
37. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
[TBL] [Abstract][Full Text] [Related]
38. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.
Clarke LE; Frauenhoffer E; Fox E; Neves R; Bruggeman RD; Helm KF
J Cutan Pathol; 2010 Jul; 37(7):737-43. PubMed ID: 20175824
[TBL] [Abstract][Full Text] [Related]
39. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
40. Angiomatoid features in fibrohistiocytic sarcomas. Immunohistochemical, ultrastructural, and clinical distinction from vascular neoplasms.
Costa MJ; McGlothlen L; Pierce M; Munn R; Vogt PJ
Arch Pathol Lab Med; 1995 Nov; 119(11):1065-71. PubMed ID: 7487409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
